首页> 外文期刊>Journal of cutaneous pathology >Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology
【24h】

Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology

机译:皮肤病病的适当使用标准:来自美国皮肤病学会的初步建议

获取原文
获取原文并翻译 | 示例
           

摘要

Background Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy and physician decision‐making. Objectives The American Society of Dermatopathology, with input from the American Academy of Dermatology and the College of American Pathologists, sought to develop AUC in dermatopathology. Methods The RAND/UCLA appropriateness methodology, which combines evidence‐based medicine, clinical experience and expert judgment, was used to develop AUC in dermatopathology. Results With the number of ratings predetermined at 3, AUC were developed for 211 clinical scenarios involving 12 ancillary studies. Consensus was reached for 188 (89%) clinical scenarios, with 93 (44%) considered “usually appropriate,” 52 (25%) “rarely appropriate” and 43 (20%) “uncertain appropriateness.” Limitations The methodology requires a focus on appropriateness without comparison between tests and irrespective of cost. Conclusions The ultimate decision of when to order specific test rests with the physician and is one where the expected benefit exceeds the negative consequences. This publication outlines the recommendations of appropriateness—AUC for 12 tests used in dermatopathology. Importantly, these recommendations may change considering new evidence. Results deemed “uncertain appropriateness” and where consensus was not reached may benefit from further research.
机译:背景技术适当的使用标准(AUC)为测试选择提供医生指导,并影响医疗保健交付,报销政策和医生决策。目标美国皮肤病学会,来自美国皮肤科学院和美国病理学家学院的意见,寻求开发皮肤病的AUC。方法采用依据基于循证医学,临床经验和专家判断的兰特/ uCLA适当性方法用于开发皮肤病病的AUC。在3,AUC预定的评级数量的结果是为1211个涉及12个辅助研究的临床情景开发。 188名(89%)临床情景达成共识,93名(44%)被认为是“通常合适”,52(25%)“很少合适”和43(20%)“不确定的适当性”。限制方法可能会重点关注适当性,而无需进行测试,而且无论成本如何。结论何时订购特定考试的最终决定与医生休息,并且是预期利益超出负面后果的那个。本出版物概述了Dermatopo病理学中使用的12个测试的适当性-AUR的建议。重要的是,这些建议可能会考虑新的证据。结果视为“不确定的适当性”,未达成共识可能会受益于进一步的研究。

著录项

  • 来源
    《Journal of cutaneous pathology》 |2018年第8期|共18页
  • 作者单位

    Departments of Dermatology and PathologySaint Louis University School of MedicineSt. Louis Missouri;

    Center for Health Outcomes ResearchSaint Louis UniversitySt. Louis Missouri;

    Departments of Dermatology and PathologyUniversity of Michigan Medical CenterAnn Arbor Michigan;

    Silver Falls DermatologySalem Oregon;

    Department of Dermatology and Laboratory Medicine and PathologyMayo ClinicRochester Minnesota;

    Department of PathologyGundersen Health SystemLa Crosse Wisconsin;

    Departments of Dermatology and PathologyStanford University School of MedicineStanford California;

    Midwest Pathology Associates LLCOverland Park Kansas;

    Departments of Dermatology and Cutaneous BiologySidney Kimmel Medical College at Thomas Jefferson;

    Department of Pathology and Laboratory MedicineDartmouth‐Hitchcock Medical Center and Geisel School;

    Departments of Dermatology and Pathology Via Christi ClinicAscension Medical GroupWichita Kansas;

    Departments of Dermatology and PathologySaint Louis University School of MedicineSt. Louis Missouri;

    Departments of Dermatology and PathologyStanford University School of MedicineStanford California;

    Department of Anatomic PathologyOakland University William Beaumont School of Medicine and Beaumont;

    Departments of Dermatology and PathologyUniversity of IowaIowa City Iowa;

    Departments of Dermatology and PathologySaint Louis University School of MedicineSt. Louis Missouri;

    Departments of Dermatology Otolaryngology and SurgeryFeinberg School of Medicine Northwestern;

    Department of PathologyUniversity of WashingtonSeattle Washington;

    Pathology Service and Dermatopathology UnitMassachusetts General Hospital and Harvard Medical;

    Department of DermatologyDermatologic Surgery Medical University of SCCharleston South Carolina;

    Department of Pathology and Molecular MedicineUniversity of AucklandAuckland New Zealand;

    Departments of Dermatology and Laboratory MedicineGeisinger Medical CenterDanville Pennsylvania;

    Departments of Dermatology and Pathology and Laboratory MedicineUniversity of California Davis;

    ProPath;

    Departments of Dermatology and PathologyUniversity of Texas Southwestern Medical;

    Departments of Pathology Dermatology &

    Genomic MedicineThe University of Texas MD Anderson Cancer;

    Departments of Dermatology and PathologyUniversity of Michigan Medical CenterAnn Arbor Michigan;

    Miraca Life SciencesIrving Texas;

    Departments of Pathology Dermatology &

    Genomic MedicineThe University of Texas MD Anderson Cancer;

    Department of DermatologyNorthwestern UniversityChicago Illinois;

    Bey Dermatology and Cosmetic SurgerySpring Hill Florida;

    Department of DermatologyYale School of MedicineNew Haven Connecticut;

    Departments of Pathology and Translational Molecular Pathology Division of Pathology and;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病学与性病学;
  • 关键词

    ancillary studies; appropriate use criteria; dermatopathology; evidence‐based medicine; expert rating;

    机译:辅助研究;适当使用标准;皮肤病学;基于证据的医学;专家评级;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号